

## Editorial

### Aurora Sheds Light on Head and Neck Squamous Cell Carcinoma.

*Commentary on Reiter et al., p. 5136*

Haiyong Han and Daniel D.Von Hoff.....5003

### Prognostic Biomarkers in Head and Neck Cancer.

*Commentary on Reiter et al., p. 5136*

Jennifer R. Grandis.....5005

## The Biology Behind

### Hypoxia-Inducible Factor-1 and p53: Friends, Acquaintances, or Strangers?

*Commentary on Sumiyoshi et al., p. 5112*

Ester M. Hammond and Amato J. Giaccia .....5007

### The Science of Selective Estrogen Receptor Modulators: Concept to Clinical Practice.

*Commentary on Lippman et al., p. 5242*

V. Craig Jordan .....5010

## CCR Practice of Translational Oncology

### Molecular Screening Testing for Colorectal Cancer.

Bernard Levin.....5014

## Molecular Pathways

### Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective.

Marcin Kowanetz and Napoleone Ferrara .....5018

## Review

### Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell-Mediated Patient-Specific Immunotherapy.

Marialisa Sensi and Andrea Anichini .....5023

## Human Cancer Biology

### Validity of Messenger RNA Expression Analyses of Human Saliva. Shalini V. Kumar,

Gregory J. Hurteau, and Simon D. Spivack.....5033

### Promoter Hypermethylation Profile of Kidney Cancer with New Proapoptotic p53 Target Genes and Clinical Implications. Frank Christoph, Steffen Weikert, Carsten Kempkensteffen,

Hans Krause, Martin Schostak, Jens Köllermann, Kurt Miller, and Mark Schrader .....5040

### Molecular Heterogeneity of Inflammatory Breast Cancer: A Hyperproliferative Phenotype.

Dang M. Nguyen, Kathy Sam, Anna Tsimelzon, Xiaoxian Li, Helen Wong, Syed Mohsin, Gary M. Clark,

Susan G. Hilsenbeck, Richard M. Elledge, D. Craig Allred, Peter O'Connell, and Jenny C. Chang.....5047

### Signal Transducers and Activators of Transcription 3 Pathway Activation in Drug-Resistant

Ovarian Cancer. Zhenfeng Duan, Rosemary Foster, Debra A. Bell, Jennifer Mahoney, Kathryn Wolak,

Ami Vaidya, Constanze Hampel, Hang Lee, and Michael V. Seiden.....5055

### Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting. John C. Sok, Francesca M. Coppelli, Sufi M. Thomas,

Miriam N. Lango, Sichuan Xi, Jennifer L. Hunt, Maria L. Freilino, Michael W. Graner, Carol J. Wikstrand,

Darell D. Bigner, William E. Gooding, Frank B. Furnari, and Jennifer R. Grandis.....5064

### Aberrant Nuclear Accumulation of Glycogen Synthase Kinase-3 $\beta$ in Human Pancreatic Cancer: Association with Kinase Activity and Tumor Dedifferentiation. Andrei V. Ougolkov,

Martin E. Fernandez-Zapico, Vladimir N. Bilim, Thomas C. Smyrk, Suresh T. Chari,

and Daniel D. Billadeau.....5074

### Rac Activation Is Associated with Hepatocellular Carcinoma Metastasis by Up-regulation of Vascular Endothelial Growth Factor Expression. Terence K. Lee, Ronnie T.P. Poon, Anthony P. Yuen,

Kwan Man, Zhen Fan Yang, Xin Yuan Guan, and Sheung Tat Fan .....5082

- Fatty Acid Binding Protein 6 Is Overexpressed in Colorectal Cancer.** Takahiro Ohmachi, Hiroshi Inoue, Koshi Mimori, Fumiaki Tanaka, Atsushi Sasaki, Tatsuo Kanda, Hiroshi Fujii, Katsuhiko Yanaga, and Masaki Mori .....5090
- The Biological Role of the Low-Affinity p75 Neurotrophin Receptor in Esophageal Squamous Cell Carcinoma.** Tomoyuki Okumura, Shigeru Tsunoda, Yukiko Mori, Tetsuo Ito, Keiji Kikuchi, Timothy Cragin Wang, Shigeru Yasumoto, and Yutaka Shimada .....5096
- DNA Repair Pathway Profiling and Microsatellite Instability in Colorectal Cancer.** Jinsheng Yu, Mary A. Mallon, Wanghai Zhang, Robert R. Freimuth, Sharon Marsh, Mark A. Watson, Paul J. Goodfellow, and Howard L. McLeod .....5104

## Imaging, Diagnosis, Prognosis

- Overexpression of Hypoxia-Inducible Factor 1 $\alpha$  and p53 Is a Marker for an Unfavorable Prognosis in Gastric Cancer.** Yasushi Sumiyoshi, Yoshihiro Kakeji, Akinori Egashira, Ken Mizokami, Hiroyuki Orita, and Yoshihiko Maehara .....5112
- Differential Expression of Neuronal Genes Defines Subtypes of Disseminated Neuroblastoma with Favorable and Unfavorable Outcome.** Matthias Fischer, André Oberthuer, Benedikt Brors, Yvonne Kahlert, Matthias Skowron, Harald Voth, Patrick Warnat, Karen Ernestus, Barbara Hero, and Frank Berthold .....5118
- A Molecular Diagnostic Test for Distinguishing Lung Adenocarcinoma from Malignant Mesothelioma Using Cells Collected from Pleural Effusions.** Andrew J. Holloway, Dileepa S. Diyagama, Ken Opeskin, Jenette Creaney, Bruce W.S. Robinson, Richard A. Lake, and David D.L. Bowtell .....5129
- Aurora Kinase A Messenger RNA Overexpression Is Correlated with Tumor Progression and Shortened Survival in Head and Neck Squamous Cell Carcinoma.** Rudolf Reiter, Peter Gais, Uta Jütting, Miriam K. Steuer-Vogt, Anja Pickhard, Karin Bink, Sandra Rauser, Silke Lassmann, Heinz Höfler, Martin Werner, and Axel Walch .....5136
- Selective Profiling of Proteins in Lung Cancer Cells from Fine-Needle Aspirates by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry.** Joseph M. Amann, Pierre Chaurand, Adriana Gonzalez, James A. Mobley, Pierre P. Massion, David P. Carbone, and Richard M. Caprioli .....5142
- Microsatellite DNA Alterations of Gastrointestinal Stromal Tumors Are Predictive for Outcome.** Paulus Schurr, Stefan Wolter, Jussuf Kaifi, Uta Reichelt, Helge Kleinhaus, Robin Wachowiak, Emre Yekebas, Tim Strate, Viacheslav Kalinin, Ronald Simon, Guido Sauter, Hansjoerg Schaefer, and Jakob Izbicki .....5151
- Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer.** Caterina Bianco, Luigi Strizzi, Mario Mancino, Aasia Rehman, Shin Hamada, Kazuhibe Watanabe, Antonella De Luca, Brenda Jones, Gabriela Balogh, Jose Russo, Daniel Mailo, Raffaele Palaia, Giuseppe D'Aiuto, Gerardo Botti, Francesco Perrone, David S. Salomon, and Nicola Normanno .....5158

## Cancer Therapy: Clinical

- Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies.** Karen W.L. Yee, Zhihong Zeng, Marina Konopleva, Srdan Verstovsek, Farhad Ravandi, Alessandra Ferrajoli, Deborah Thomas, William Wierda, Efrosyni Apostolidou, Maher Albitar, Susan O'Brien, Michael Andreeff, and Francis J. Giles .....5165
- The Effect of Enzyme-Inducing Antiepileptic Drugs on the Pharmacokinetics and Tolerability of Procarbazine Hydrochloride.** Stuart A. Grossman, Kathryn A. Carson, Tracy T. Batchelor, Glenn Lesser, Tom Mikkelsen, Jane B. Alavi, Surasak Phuphanich, Tarek Hammour, Joy D. Fisher, and Jeffrey G. Supko .....5174
- A Phase I Pharmacokinetic Study of HMN-214, a Novel Oral Stilbene Derivative with Polo-Like Kinase-1-Interacting Properties, in Patients with Advanced Solid Tumors.** Linda L. Garland, Charles Taylor, Deborah L. Pilkington, Jan L. Cohen, and Daniel D. Von Hoff .....5182
- High-Dose Celecoxib and Metronomic "Low-dose" Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non-Hodgkin's Lymphoma.** Rena Buckstein, Robert S. Kerbel, Yuval Shaked, Rakesh Nayar, Cindy Foden, Ruth Turner, Christine R. Lee, Diane Taylor, Liying Zhang, Shan Man, Sylvain Baruchel, Diana Stempak, Francesco Bertolini, and Michael Crump .....5190

---

**Antitumor Effects of a Novel Phenylbutyrate-Based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer.** Samuel K. Kulp, Chang-Shi Chen, Da-Sheng Wang, Ching-Yu Chen, and Ching-Shih Chen .....5199

**Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors.** Alain C. Mita, Lisa A. Hammond, Peter L. Bonate, Geoffrey Weiss, Heather McCreery, Samira Syed, Mitchell Garrison, Quincy S.C. Chu, Johann S. DeBono, Christopher B. Jones, Steve Weitman, and Eric K. Rowinsky .....5207

## Cancer Therapy: Preclinical

**Adenovirus-Mediated *Calponin h1* Gene Therapy Directed against Peritoneal Dissemination of Ovarian Cancer: Bifunctional Therapeutic Effects on Peritoneal Cell Layer and Cancer Cells.** Tomonori Ogura, Hiroaki Kobayashi, Yousuke Ueoka, Kaoru Okugawa, Kiyoko Kato, Toshio Hirakawa, Shigenari Hashimoto, Shun'ichiro Taniguchi, Norio Wake, and Hitoo Nakano .....5216

**Eliminating Established Tumor in nu/nu Nude Mice by a Tumor Necrosis Factor- $\alpha$ -Related Apoptosis-Inducing Ligand-Armed Oncolytic Adenovirus.** Fengqin Dong, Li Wang, John J. Davis, Wenxian Hu, Lidong Zhang, Wei Guo, Fuminori Teraishi, Lin Ji, and Bingliang Fang .....5224

**Preclinical Characterization of AEG35156/GEM 640, a Second-Generation Antisense Oligonucleotide Targeting X-Linked Inhibitor of Apoptosis.** Eric C. LaCasse, Gabriele G. Cherton-Horvat, Kimberley E. Hewitt, Lori J. Jerome, Stephen J. Morris, Ekambar R. Kandimalla, Dong Yu, Hui Wang, Wei Wang, Ruiwen Zhang, Sudhir Agrawal, John W. Gillard, and Jon P. Durkin .....5231

## Cancer Susceptibility and Prevention

**Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk.** Marc E. Lippman, Steven R. Cummings, Damon P. Disch, John L. Mershon, Sherie A. Dowsett, Jane A. Cauley, and Silvana Martino .....5242

**Liver Intestine-Cadherin (*CDH17*) Haplotype Is Associated with Increased Risk of Hepatocellular Carcinoma.** Xiao Qi Wang, John M. Luk, Mercè Garcia-Barcelo, Xiaoping Miao, Pauline P. Leung, David W. Ho, Siu Tim Cheung, Brian Y. Lam, Cindy K. Cheung, Ashley S. Wong, Silvana S. Lau, Man Ting So, Wan Ching Yu, Qi Cai, Karen S. Liu, Chee Kin Hui, George K. Lau, Ronnie T.P. Poon, John Wong, and Sheung Tat Fan .....5248

## Letters to the Editor


**Mononuclear Infiltrates in Osteosarcoma and Chemokine Receptor Expression.** Irene von Luetlichau, Michaela Nathrath, Stefan Burdach, Ralf Huss, Stephan Segerer, and Peter J. Nelson .....5253

**Reply to Letter to the Editor by Luetlichau et al.** Caroline Laverdière and Richard Gorlick .....5254

---

## About the Cover

X-linked inhibitor of apoptosis (XIAP) represents a novel therapeutic target for the induction of tumor apoptosis by a new investigational, second-generation antisense drug, AEG35156. Illustrated is the strong protein expression of XIAP within a non-small-cell lung cancer tumor xenograft, in the absence of AEG35156 treatment, using immunohistochemistry. AEG35156 treatment of tumor-bearing mice results in XIAP down-regulation and tumor regression when used as a single agent or in combination with chemotherapy. For further details, please see LaCasse *et al.* on page 5231 in this issue.



# Clinical Cancer Research

12 (17)

*Clin Cancer Res* 2006;12:5003-5254.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/12/17>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/12/17>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.